Bucket Shops

More on the Kerr family connections – SEFE

One of the SEFE directors stands out from the rest, thirty year old Shannon Kerr. There are were some wonderful pictures of Shannon and her friends in London, in Las Vegas, and elsewhere on her Facebook page (UPDATE: No longer available, but it was here). One can see that Shannon is an attractive, and now, thanks to her SEFE shares, a wealthy young woman. But she has seen some tragedy in her life as well, including her father’s arrest in January of this year and her husband’s unfortunate passing in 2011. Still, it does appear that SEFE stock should have made her a millionaire many times over.

Just for fun, lets take a closer look at her resume. Here is the one from the most recent SEFE 10K filing:

(more…)

Humble Harold Sciotto (SEFE, ECTY, AUGT, SPDL)

In The Mass Psychology of Suckers, Parts 1 and 2, we began exploring the chronology of Sefe, Inc. (SEFE) and the players involved. We will continue with another installment in that series soon, but today let’s take a look at SEFE director “Humble” Harold Sciotto.

Harold joined the board of SEFE last summer, the June 20, 2011 8k filing announcing his arrival discussed his background:

(more…)

Like Father, Like Daughter? The Kerr Family and Sefe, Inc. – SEFE

April 25th was a busy day for Sefe, Inc. (SEFE fka MDCL). Before the open they issued a very late Form D and after the close they issued a new 8k. This new filing described a financing they had just completed, The company states:

On April 25, 2012 (“Issuance Date”), the Registrant entered into a Securities Purchase Agreement (the “SPA”), with Riverbend, LLC (the “Riverbend”), whereby Riverbend agrees to purchase, and the Registrant agrees to issue, Debentures up to a total principal amount of $2,000,000 with warrants attached to purchase up to 500,000 shares of common stock of the Registrant at $1.00 per share. Subsequent purchases shall be mutually agreed upon. Each Debenture will accrue interest on the unpaid principal of each individual Debenture at the rate of eight percent (8%) per year (computed on the basis of a 365-day year and the actual days elapsed) from the date each Debenture is created until paid. The Registrant shall have the option to repay the entire principal amount and all accrued interest at any time on or before the Due Date.

On the Issuance Date, the first closing occurred, whereby a Debenture was issued to Riverbend in the aggregate amount of $200,000. All principal and interest accrued thereupon shall be due and payable on or before April 24, 2013.

And just who is their benefactor?

(more…)

Covering their tracks? (SEFE)

Let’s take another quick break from our chronological look at current reverse-merger darling SEFE, Inc. (SEFE), to examine this morning’s Form D filing from the company.

Form D filings are required when a company attempts to raise money under one of the Reg D exemptions to the registration requirements of the SEC. Essentially, the company is attempting to sell unregistered securites. The rules are very clear, and one of the rules concerns when the Form D must be submitted:

An issuer must file a new notice with the SEC for each new offering of securities no later than 15 calendar days after the “date of first sale” of securities in the offering

So, if a company met the Reg D exemption and were to sell stock on April 10, 2012, they would need to file their Form D today.

On SEFE‘s newly filed Form D, available here, they announce that this is a new notice and they wish to raise $8mm under Rule 506. As of the date of the notice they have raised $854,500.00. Not very impressive fundraising for a company with a stock as hot as SEFE‘s.

But that is not the fascinating part. The filing gets quite interesting when one examines the date of first sale. It is April 13, 2011.

SEFE is a little less than a year delinquent on this filing. So is the company trying to cover up their tracks?

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

The Mass Psychology of Suckers Part 2 – Sefe, Inc. (SEFE)

When we ended The Mass Psychology of Suckers Part 1, we were examining the unique resume of SEFE (aka Midnight Candle) CFO, Patrick Deparini. At first glance he appears to be an odd choice as CFO. He had no real experience working in finance, nor in the candle business. His real job was as a paralegal at the law firm of Harold P. Gewerter, Esq. Ltd.

Harold Gewerter’s most famous client, John Edwards*, was mighty busy by the mid-00s. Not only was John the mastermind behind the CMKX fraud, but he was also behind Pinnacle Business Management (PBCM), US Canadian Minerals (UCAD), St. George Minerals (SGGM), BioTech Medics (BMCS), Global Diamond Exchange (GBDX), Equitable Mining (EQBM), OMDA Oil and Gas (OOAG), and Grand Entertainment & Music (GMSC). Read more in this excellent piece by Janice Shell, here, or go to Pacer, and read the entire USA v. Turino, Edwards, et. al. indictment of March 24, 2010.

So, perhaps some of John’s industriousness rubbed off on Patrick, for soon Patrick started his very own little shell company. In late 2004, young Patrick, then only 29, was listed as the CEO and majority shareholder of Las Vegas based Nascent Wine Company (NCTW) today a pink sheet stock that sells for less than 1/4 of a cent per share.

How did SEFE (fka MDCL) CEO, Helen C. Cary, sitting in Indio, CA and Patrick Deparini, in the offices of a sleazy law firm in Las Vegas, find one another?

(more…)

Gene Michael, Richard, Last One to Leave Please Turn Off the Lights! (KUN)

Turning away from SEFE for just a moment, do any readers remember China Shenghuo Pharmaceutical Holdings (KUN)? KUN was one of the many Chinese reverse merger darlings to come out of Richard Rappaport‘s bucket shop Westpark Capital. The one that featured the illustrious and unforgettable Gene Michael Bennett on the Board of Directors. Late last week, in a fit of pique, the company announced that it cannot be fired, because it has already quit! In the press release, the company states that in the opinion of the NYSE Amex:

(more…)

The Mass Psychology of Suckers Part 1 – Sefe, Inc. (SEFE)

Every once in a while someone will ask us here at BuyersStrike! about a small company that is, in our eyes, obviously a stock promotion. But to some it seems real. They want to believe it is real. And now is one of those times. Introducing SEFE, Inc. (SEFE), a company that hits new highs on increasing volume every single day. A company that today possesses a market cap of over $110mm, but at the end of 2011 had less than $6000.00 in the bank.

SEFE is also the newest client of Geoffrey Eiten‘s notorious stock pumping investor relations shop OTC Financial Network aka National Financial Communications, and Paul Cohen‘s ridiculous Grassroots Research aka Cohen Research. More on those two fine fellows in a bit, but first lets look at the origins of SEFE, Inc.

(more…)

Quick Take – The Uri Landesman Magical Mystery Tour (ECTE, NEOP)

Our good friend, and Mark Nordlicht‘s right hand man, Uri Landesman was back on the air this holiday-shortened week, discussing everyone’s favorite tired old bio-dreck, reverse merger company Echo Therapeutics (ECTE) and bucket shop IPO Neoprobe (NEOP). Read more about ECTE here, and a great piece on NEOP, by Martin Shkreli, here. And check out Uri’s performance!

Happy Holidays!

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.

When is a ‘Clinical Trial’ not a Clinical Trial? (ECTE)

Remember Echo Therapeutics (ECTE), that wonderful little reverse-merger bio-dreck company formerly known as Sontra and so loved by Florida bucket shopsUri Landesman and Mark Nordlicht? The firm issued a press release last week trumpeting yet another “successful clinical trial”. The headline reads (emphasis ours):

Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes

Being a curious sort, your author decided to take a look at the details of the clinical trial. Not by reading press releases, but by actually looking up the study. But when is a ‘Clinical Trial’ not a clinical trial? When you cannot find it on Clinicaltrials.gov perhaps? A search of the Clinicaltrials.gov database, try it yourself here, yielded absolutely no hits (see here) for any studies sponsored by Echo Therapeutics (ECTE). Yet, the company cheerfully continues in its press release:

(more…)

Quick Take – Advanced Battery CFO flies the coop (ABAT)

This morning beleaguered Advanced Battery Tech (ABAT), plaything of promoter John C. Leo (of MH Myerson infamy), and one of a ring of Chinese reverse-merger companies that shares offices and much more (read about that here), issued a very brief 8k stating:

On October 25, 2011 Guohua Wan submitted her resignation from her position as the Registrant’s Chief Financial Officer and from her position as a member of the Board of Directors. Ms. Wan stated that she was resigning in order to attend to personal matters.

Perhaps she was tired of signing off on 10Ks and 10Qs with what any reasonable investor could conclude are material omissions with respect to related party transactions?

The content contained in this blog represents only the opinions of the author. The author may hold either long or short positions in securities of various companies discussed in the blog. This commentary in no way constitutes investment advice, and should never be relied on in making an investment decision, ever. This blog is not a solicitation of business: all inquiries will be ignored. The content herein is intended solely for the entertainment of the reader, and the author.